Goldman Sachs
AVEO

Goldman Sachs’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Goldman Sachs’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-180
Closed -$2K – 7441
2015
Q4 		$2K Buy
+180
New +$2.14K ﹤0.01% 7091

Goldman Sachs's AVEO Position: Q1 2023 in Review

Goldman Sachs sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 642,652 shares — an estimated $9.61M sold.

Goldman Sachs first reported a position in AVEO in Q2 2013 and held it in 33 quarters. The position peaked at $9.61M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Goldman Sachs reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 642,652 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $9.61M.
  • Goldman Sachs first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
  • Goldman Sachs's AVEO Pharmaceuticals, Inc. position peaked at $9.61M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.